This review paper examines how cold tumor biology and mitochondrial stress connect, exploring what the cGAS-STING pathway reveals about cold tumor how to make immunotherapy work.
If you have been told your tumor is “cold,” you already know what that means in practice: immunotherapy did not work, or was never likely to. The question of how to make immunotherapy work in cold tumors is one of the most actively researched problems in oncology right now, and most of the proposed answers have focused on what immune cells are doing wrong. A review paper published in the Journal of Translational Medicine shifts that focus inward, toward the cancer cell’s own energy machinery, and the picture that emerges is worth understanding.
The stakes here are real for a specific group of patients: those whose tumors have already resisted checkpoint inhibitors or other immune-based approaches. What shifts by the end of this post is not a treatment option, but a mechanistic explanation that may help you understand why certain clinical trials are pairing older-style cancer drugs with immunotherapy, and why that pairing is not arbitrary.
What the Standard Account Leaves Out
The standard explanation for immunotherapy failure points to a lack of immune cell infiltration in cold tumors, or to suppressive signals in the tumor microenvironment. Both are true. But they describe the problem at the level of the neighborhood, not the house. What this review asks is a more upstream question: why did the immune system never get the call in the first place? Oncologists have known for some time that cancer cells silence immune detection, but the molecular wire connecting mitochondrial stress to that silencing has not been laid out in a unified way until now.
A Severed Wire and a Live Signal
Picture a building where an intruder has quietly snipped the wire to the smoke alarm so they can move through every room without triggering a response. The intruder moves freely because the security system never receives a signal. Now picture someone deliberately reconnecting that wire, not to create an emergency, but to restore the system’s ability to detect one.
In this analogy, the intruder is the cancer cell, and the severed wire is the suppressed signaling pathway that would normally alert the immune system to danger. The smoke alarm hardware, the cGAS-STING proteins and interferon pathways, represents the immune alarm system that sits waiting inside cells. The wire itself is mitochondrial DNA, which leaks out of stressed or damaged mitochondria into the surrounding cell interior. When that DNA leaks, the alarm proteins read it as a sign of viral infection, because mitochondria carry their own ancient genetic material that the immune system cannot easily distinguish from a pathogen’s. In the lab, this chain of events is called viral mimicry, and researchers are asking whether it can be deliberately triggered in tumors that have learned to keep the alarm off permanently.
The Mechanism, and What the Review Synthesizes
Mitochondria are the cell’s energy-producing compartments, but they are also, under stress, inadvertent broadcasters. When mitochondrial integrity is compromised, whether by drug treatment, metabolic pressure, or other cellular stress, their DNA escapes into the cytoplasm. The immune proteins cGAS and STING detect that DNA and initiate an interferon response, the body’s standard antiviral alarm. That alarm, if it fires strongly enough inside a tumor, can signal immune cells to treat the tumor as a threat worth attacking.
Cancer cells suppress this entire pathway through epigenetic silencing, a process where chemical modifications to DNA effectively turn off the genes needed to broadcast the alarm. This review, authored by Nesci, Marchi, Hu, Marincola, and Algieri, synthesizes existing preclinical and clinical research to argue that mitochondrial stress-induced viral mimicry is not a peripheral curiosity but a central, targetable mechanism connecting tumor immune evasion to that epigenetic silencing. Because this is a review paper, it does not report original experimental statistics. Its contribution is conceptual: it assembles the evidence into a framework that had not been unified in this way before.
The TAM Connection
Francesco Marincola, affiliated with TAM Center, is a co-author on this paper. His involvement situates TAM’s research program within the broader scientific effort to understand immune evasion at a mechanistic level, and connects TAM’s translational focus directly to this emerging framework.
Where This Research Points
The framework described in this review opens a specific investigational direction: combining agents that deliberately stress or damage mitochondria with immunotherapy, on the hypothesis that triggering mitochondrial DNA leakage will reactivate the viral mimicry alarm and convert a cold tumor into one the immune system can recognize and attack. This is not a proven clinical strategy. It is a hypothesis with enough mechanistic support to justify designing trials around it, and some of those trials are already forming. What remains to be established is which mitochondria-targeting agents produce the right kind of stress, in which tumor types, at which doses, without overwhelming the patient’s healthy cells in the process. Those are hard questions, and answering them will take time.
What You Can Do Now
If your tumor has been described as cold, or if you have not responded to immunotherapy, ask your oncologist whether any trials pairing mitochondria-targeting agents with checkpoint inhibitors are currently open at your center or at centers you can access. Understanding the mechanism does not change your options today, but it can sharpen the questions you ask. The field is building the conceptual scaffolding to design better combinations, and the patients who will benefit most are the ones who stay close enough to the research to recognize a relevant trial when it opens.
Source
Nesci S; Marchi S; Hu J; Marincola FM; Algieri C. “Inflammatory mitochondrial signalling and viral mimicry in cancer.” Journal of Translational Medicine 2025;23(1):982. doi:10.1186/s12967-025-06931-3. https://doi.org/10.1186/s12967-025-06931-3
Source
Nesci S; Marchi S; Hu J; Marincola FM; Algieri C. “Inflammatory mitochondrial signalling and viral mimicry in cancer.” Journal of Translational Medicine 2025;23(1):982. doi:10.1186/s12967-025-06931-3. https://doi.org/10.1186/s12967-025-06931-3
Frequently Asked Questions
When mitochondria are stressed or damaged, they can leak their own DNA into the interior of the cell. The immune system reads this leaked DNA as a sign of viral infection and triggers alarm pathways, called cGAS-STING and interferon signaling, that are normally reserved for fighting viruses. Researchers call this process viral mimicry because the cell is generating a false virus alarm from its own damaged components.
The review paper describes how cancer cells can actively suppress the mitochondrial stress signals that would otherwise alert the immune system to attack the tumor. Without those alarm signals firing, immune cells may not recognize or target the cancer effectively. This suppression of viral mimicry is one proposed biological explanation for why certain tumors resist immunotherapy.
This is a review paper, meaning the authors synthesized and interpreted findings from existing preclinical and clinical research rather than running new experiments. No original patient data or experimental statistics were produced by this paper itself. Its contribution is in connecting existing lines of research to identify mitochondrial signaling as a potentially exploitable target.
The paper points toward combination strategies that would pair mitochondria-targeting treatments with existing immunotherapy drugs, with the idea that deliberately triggering the viral mimicry alarm could make immune-resistant tumors visible to the immune system again. These approaches are investigational and have not been established as clinically effective. The research identifies a direction worth pursuing in future trials rather than a treatment ready for patients.
Many tumors silence the specific molecular pathways that would flag them as dangerous to immune cells. If a therapy can reactivate those pathways at the right point in the signaling chain, it could restore immune recognition without requiring entirely new drug classes. Understanding exactly how mitochondrial signals feed into immune activation helps researchers design combinations that address the suppression directly.
Yes, Francesco Marincola of TAM Center is a co-author on this review paper. His involvement reflects TAM Center’s focus on translational research that connects laboratory findings to clinical application in oncology and immunotherapy.
No, this is not a treatment available anywhere. The paper reviews existing research and describes mechanisms and strategies that remain investigational. Any clinical applications based on these findings would need to be tested and validated through formal clinical trials before becoming available to patients.
Interested in what targeted diagnostics could reveal about your own biology? Start with a conversation with the TAM Center team.
Schedule a Consultation